{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:13:16Z","timestamp":1790730796437,"version":"4.1.0"},"reference-count":187,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.autrev.2022.103114","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T13:55:20Z","timestamp":1652795720000},"page":"103114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications"],"prefix":"10.1016","volume":"21","author":[{"given":"Piero","family":"Ruscitti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Di Cola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Di Muzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ursini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2022.103114_bb0005","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbagen.2010.03.011","article-title":"Serum ferritin: Past, present and future","volume":"1800","author":"Wang","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.autrev.2022.103114_bb0010","first-page":"1575","article-title":"Sur la cristallisation de la ferritine","volume":"19","author":"Laufberger","year":"1937","journal-title":"Bulletin de la Societe de chimie biologique."},{"key":"10.1016\/j.autrev.2022.103114_bb0015","doi-asserted-by":"crossref","first-page":"12638","DOI":"10.1016\/S0021-9258(18)37801-3","article-title":"The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene","volume":"263","author":"Torti","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2022.103114_bb0020","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1182\/blood.V99.10.3505","article-title":"Regulation of ferritin genes and protein","volume":"99","author":"Torti","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103114_bb0025","doi-asserted-by":"crossref","first-page":"mfab021","DOI":"10.1093\/mtomcs\/mfab021","article-title":"Chemistry and biology of ferritin","volume":"13","author":"Plays","year":"2021","journal-title":"Metallomics"},{"key":"10.1016\/j.autrev.2022.103114_bb0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaut.2007.11.003","article-title":"New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity","volume":"30","author":"Recalcati","year":"2008","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103114_bb0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.blre.2008.08.001","article-title":"Ferritin for the clinician","volume":"23","author":"Knovich","year":"2009","journal-title":"Blood Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/1741-7015-11-185","article-title":"The hyperferritinemic syndrome: macrophage activation syndrome, Still\u2019s disease, septic shock and catastrophic antiphospholipid syndrome","volume":"11","author":"Ros\u00e1rio","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102573","article-title":"COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?","volume":"19","author":"Colafrancesco","year":"2020","journal-title":"Autoimmun Rev."},{"issue":"11","key":"10.1016\/j.autrev.2022.103114_bb0050","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3389\/fimmu.2020.01130","article-title":"Severe COVID-19, another piece in the puzzle of the hyperferritinemic syndrome. an immunomodulatory perspective to alleviate the storm","volume":"28","author":"Ruscitti","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.autrev.2022.103114_bb0055","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ajem.2021.04.088","article-title":"Ferritin, fever, and frequent visits: Hyperferritinemic syndromes in the emergency department","volume":"48","author":"Annous","year":"2021","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/intimm\/dxy012","article-title":"Convergent pathways of the hyperferritinemic syndromes","volume":"30","author":"Schulert","year":"2018","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2022.103114_bb0065","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/hep.22716","article-title":"Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta\/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells","volume":"49","author":"Ruddell","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2022.103114_bb0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.autrev.2007.01.016","article-title":"Ferritin in autoimmune diseases","volume":"6","author":"Zandman-Goddard","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0075","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0167-4889(00)00066-5","article-title":"Interleukin-1beta increases binding of the iron regulatory protein and the synthesis of ferritin by increasing the labile iron pool","volume":"1497","author":"Pi\u00f1ero","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.autrev.2022.103114_bb0080","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0006-291X(90)91466-6","article-title":"Interleukin 1 induces ferritin heavy chain in human muscle cells","volume":"169","author":"Wei","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.autrev.2022.103114_bb0085","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.0105-2896.2010.00903.x","article-title":"TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity","volume":"235","author":"Freeman","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1600-065X.2009.00772.x","article-title":"The costimulatory role of TIM molecules","volume":"229","author":"Rodriguez-Manzanet","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0095","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1084\/jem.20042433","article-title":"TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis","volume":"202","author":"Chen","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0100","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nri1111","article-title":"The TIM gene family: emerging roles in immunity and disease","volume":"3","author":"Kuchroo","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2022.103114_bb0105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1084\/jem.20050308","article-title":"Tim-2 regulates T helper type 2 responses and autoimmunity","volume":"202","author":"Chakravarti","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fimmu.2019.00131","article-title":"Ferritin light chain confers protection against sepsis-induced inflammation and organ injury","volume":"10","author":"Zarjou","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103114_bb0115","doi-asserted-by":"crossref","first-page":"12232","DOI":"10.1038\/s41598-020-69031-w","article-title":"Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations","volume":"10","author":"Ruscitti","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2022.103114_bb0120","first-page":"uxac014","article-title":"The hyper-expression of NLRP4 characterises the occurrence of macrophage activation syndrome assessing STING pathway in adult onset still\u2019s disease","author":"Ruscitti","year":"2022","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1016\/j.autrev.2022.103114_bb0125","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.molcel.2016.08.029","article-title":"USP38 Inhibits Type I Interferon Signaling by Editing TBK1 Ubiquitination through NLRP4 Signalosome","volume":"64","author":"Lin","year":"2016","journal-title":"Mol Cell"},{"key":"10.1016\/j.autrev.2022.103114_bb0130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ni.2239","article-title":"NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4","volume":"13","author":"Cui","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2022.103114_bb0135","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.autrev.2015.01.004","article-title":"Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still\u2019s disease, developing macrophage activation syndrome, correlate with the severity of the disease","volume":"14","author":"Ruscitti","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/cei.12826","article-title":"H-ferritin and CD68(+) \/H-ferritin(+) monocytes\/macrophages are increased in the skin of adult-onset Still\u2019s disease patients and correlate with the multi-visceral involvement of the disease","volume":"186","author":"Ruscitti","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2022.103114_bb0145","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/cei.12738","volume":"183","author":"Ruscitti","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2022.103114_bb0150","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/cei.13057","article-title":"jh and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome","volume":"191","author":"Ruscitti","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2022.103114_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102369","article-title":"Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases","volume":"18","author":"Di Benedetto","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.708186","article-title":"Macrophages: the good, the bad, and the gluttony","volume":"12","author":"Ross","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103114_bb0165","first-page":"662","article-title":"The hyperferritinemic syndromes and CD163: a marker of macrophage activation","volume":"16","author":"Colafrancesco","year":"2014","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2022.103114_bb0170","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2009-11-253815","article-title":"Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway","volume":"116","author":"Cohen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103114_bb0175","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3390\/biomedicines9111508","article-title":"Increased lipid peroxidation may be linked to ferritin levels elevation in adult-onset still\u2019s disease","volume":"9","author":"Chen","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2022.103114_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255493","article-title":"Clinical relevance for circulating cold-inducible RNA-binding protein (CIRP) in patients with adult-onset Still\u2019s disease","volume":"16","author":"Fujita","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2022.103114_bb0185","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1093\/rheumatology\/keaa135","article-title":"Serum sTREM-1 in adult-onset Still\u2019s disease: a novel biomarker of disease activity and a potential predictor of the chronic course","volume":"59","author":"Wang","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 121","key":"10.1016\/j.autrev.2022.103114_bb0190","first-page":"67","article-title":"The levels of CXCL12 and its receptor, CXCR4, as a biomarker of disease activity and cutaneous manifestation in adult-onset Still\u2019s disease","volume":"37","author":"Han","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0195","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","article-title":"A comprehensive review on adult onset Still\u2019s disease","volume":"93","author":"Giacomelli","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103114_bb0200","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.autrev.2014.08.032","article-title":"Adult onset Still\u2019s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions","volume":"13","author":"Maria","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0205","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","article-title":"Adult-onset still\u2019s disease","volume":"13","author":"Gerfaud-Valentin","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0210","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.semarthrit.2017.07.005","article-title":"Validation of the Fautrel classification criteria for adult-onset Still\u2019s disease","volume":"47","author":"Lebrun","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103114_bb0215","first-page":"322","article-title":"Diagnostic value of ferritin and glycosylated ferritin in adult onset Still\u2019s disease","volume":"28","author":"Fautrel","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155642","article-title":"Biomarker screening and validation for the differentiation of bloodstream infection from adult-onset Still\u2019s disease: A prospective cohort study","volume":"146","author":"Zhang","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.autrev.2022.103114_bb0225","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10067-020-05266-2","article-title":"Systemic immune-inflammation index combined with ferritin can serve as a reliable assessment score for adult-onset Still\u2019s disease","volume":"40","author":"Kim","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0230","first-page":"890","article-title":"Serum ferritin and isoferritins are tools for diagnosis of active adult Still\u2019s disease","volume":"21","author":"Van Reeth","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0235","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/ard.59.5.347","article-title":"Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still\u2019s disease","volume":"59","author":"Vignes","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103114_bb0240","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1586\/1744666X.2015.1037287","article-title":"Presentation and diagnosis of adult-onset Still\u2019s disease: the implications of current and emerging markers in overcoming the diagnostic challenge","volume":"11","author":"Colafrancesco","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2022.103114_bb0245","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00005792-200205000-00003","article-title":"Proposal for a new set of classification criteria for adult-onset still disease","volume":"81","author":"Fautrel","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2022.103114_bb0250","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.23415","article-title":"Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome","volume":"58","author":"Fardet","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103114_bb0260","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1297-319X(02)00409-8","article-title":"Ferritin levels in adult Still\u2019s disease: any sugar?","volume":"69","author":"Fautrel","year":"2002","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2022.103114_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123184","article-title":"Measurement of glycosylated ferritin with Concanavalin A: Assay design, optimization and validation","volume":"1194","author":"Raynor","year":"2022","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.autrev.2022.103114_bb0270","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.3899\/jrheum.100247","article-title":"Clinical manifestations but not cytokine profiles differentiate adult-onset Still\u2019s disease and sepsis","volume":"37","author":"Rau","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0275","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","article-title":"Adult Still\u2019s disease: manifestations, disease course, and outcome in 62 patients","volume":"70","author":"Pouchot","year":"1991","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2022.103114_bb0280","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fphar.2017.00369","article-title":"Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still\u2019s Disease: A Multicentre Retrospective Observational Study","volume":"8","author":"Colafrancesco","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2022.103114_bb0285","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001554","article-title":"Efficacy of anakinra in refractory adult-onset still\u2019s disease: multicenter study of 41 patients and literature review","volume":"94","author":"Ortiz-Sanju\u00e1n","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2022.103114_bb0290","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semarthrit.2020.10.011","article-title":"Outcome of refractory to conventional and\/or biologic treatment adult Still\u2019s disease following canakinumab treatment: Countrywide data in 50 patients","volume":"51","author":"Laskari","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103114_bb0295","doi-asserted-by":"crossref","first-page":"8054961","DOI":"10.1155\/2020\/8054961","article-title":"Real-life data on the efficacy of canakinumab in patients with adult-onset still\u2019s disease","volume":"2020","author":"Vitale","year":"2020","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.autrev.2022.103114_bb0300","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/art.38398","article-title":"Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still\u2019s disease: multicenter retrospective open-label study of thirty-four patients","volume":"66","author":"Ortiz-Sanju\u00e1n","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0305","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10067-013-2381-5","article-title":"Tocilizumab for the treatment of adult-onset Still\u2019s disease: results from a case series","volume":"33","author":"Cipriani","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0310","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/acr.20319","article-title":"Tocilizumab in refractory adult Still\u2019s disease: Refractory ASD and Tocilizumab","volume":"63","author":"Pu\u00e9chal","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2022.103114_bb0315","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1093\/rheumatology\/keaa904","article-title":"Dissecting the clinical heterogeneity of adult-onset Still\u2019s disease: results from a multi-dimensional characterization and stratification","volume":"60","author":"Berardicurti","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103114_bb0320","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/1346-8138.12033","article-title":"Clinical predictors in adult-onset Still disease: there is no getting away from ferritin and arthritis","volume":"40","author":"Colina","year":"2013","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0325","doi-asserted-by":"crossref","first-page":"12455","DOI":"10.1038\/s41598-021-91613-5","article-title":"The joint involvement in adult onset Still\u2019s disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile","volume":"11","author":"Ruscitti","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2022.103114_bb0330","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-021-02708-3","article-title":"Latent class analysis of 216 patients with adult-onset Still\u2019s disease","volume":"24","author":"Sugiyama","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2022.103114_bb0335","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1007\/s10067-021-05722-7","article-title":"Identification of prognostic factors and construction of a nomogram for patients with relapse\/refractory adult-onset Still\u2019s disease","volume":"40","author":"Yin","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0340","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s10067-010-1516-1","article-title":"Clinical features and prognosis in adult-onset Still\u2019s disease: a study of 104 cases","volume":"29","author":"Kong","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0345","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13075-021-02631-7","article-title":"Catastrophic adult-onset Still\u2019s disease as a distinct life-threatening clinical subset: case-control study with dimension reduction analysis","volume":"23","author":"Wahbi","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2022.103114_bb0350","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2022.103114_bb0355","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-041610-134208","article-title":"Familial and acquired hemophagocytic lymphohistiocytosis","volume":"63","author":"Janka","year":"2012","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0360","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","article-title":"Hemophagocytic Lymphohistiocytosis","volume":"13","author":"Al-Samkari","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.autrev.2022.103114_bb0365","first-page":"1414","article-title":"Haemophagocytic syndrome in rheumatic patients. A systematic review","volume":"16","author":"Atteritano","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.autrev.2022.103114_bb0370","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.autrev.2016.09.016","article-title":"Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers","volume":"16","author":"Ruscitti","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0375","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0380","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1097\/MPH.0b013e31824227b9","article-title":"Serum ferritin is a cost-effective laboratory marker for hemophagocytic lymphohistiocytosis in the developing world","volume":"34","author":"Switala","year":"2012","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.autrev.2022.103114_bb0385","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12185-009-0391-5","article-title":"Early diagnostic value of low percentage of glycosylated ferritin in secondary hemophagocytic lymphohistiocytosis","volume":"90","author":"Wang","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.autrev.2022.103114_bb0390","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0609.1997.tb00984.x","article-title":"Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases","volume":"59","author":"Kaito","year":"1997","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.autrev.2022.103114_bb0395","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1056\/NEJM198702053160617","article-title":"Hyperferritinemia in malignant histiocytosis and virus-associated hemophagocytic syndrome","volume":"316","author":"Esumi","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0400","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.mayocp.2013.12.012","article-title":"Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis","volume":"89","author":"Parikh","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2022.103114_bb0405","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.23911","article-title":"Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis","volume":"90","author":"Otrock","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2022.103114_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235326","article-title":"Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still\u2019s disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort","volume":"15","author":"Di Benedetto","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2022.103114_bb0415","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/jcm11010206","article-title":"Detection and prediction of macrophage activation syndrome in still\u2019s disease","volume":"11","author":"Javaux","year":"2021","journal-title":"J Clin Med"},{"issue":"Suppl. 132","key":"10.1016\/j.autrev.2022.103114_bb0420","doi-asserted-by":"crossref","first-page":"59","DOI":"10.55563\/clinexprheumatol\/lp2u7g","article-title":"Clinical characteristics of macrophage activation syndrome in adult-onset Still\u2019s disease","volume":"39","author":"Gao","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0430","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/ijlh.12713","article-title":"Diagnostic and prognostic value of low percentage of glycosylated ferritin in acquired hemophagocytic lymphohistiocytosis: A single-center study","volume":"39","author":"Nabergoj","year":"2017","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.autrev.2022.103114_bb0435","first-page":"29","article-title":"Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society","volume":"18","author":"Henter","year":"1991","journal-title":"Semin Oncol"},{"key":"10.1016\/j.autrev.2022.103114_bb0445","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/pbc.22774","article-title":"Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality","volume":"56","author":"Lin","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.autrev.2022.103114_bb0450","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.berh.2012.07.005","article-title":"Catastrophic antiphospholipid syndrome (CAPS)","volume":"26","author":"Sciascia","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0455","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1177\/0961203313504633","article-title":"Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS)","volume":"22","author":"Agmon-Levin","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2022.103114_bb0460","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12016-011-8264-0","article-title":"Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients","volume":"44","author":"Zandman-Goddard","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2022.103114_bb0465","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s002960000083","article-title":"Serum ferritin as a serologic marker of activity in systemic lupus erythematosus","volume":"20","author":"Lim","year":"2001","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2022.103114_bb0470","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/03009740310003712","article-title":"The relationship between serum ferritin levels and disease activity in systemic lupus erythematosus","volume":"32","author":"Beyan","year":"2003","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0475","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/03009740310002489","article-title":"Profiles of the acute-phase reactants C-reactive protein and ferritin related to the disease course of patients with systemic lupus erythematosus","volume":"32","author":"Hesselink","year":"2003","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0480","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3899\/jrheum.200292","article-title":"Predicting macrophage activation syndrome in childhood-onset systemic lupus erythematosus patients at diagnosis","volume":"48","author":"Gerstein","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0485","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mus.24566","article-title":"An overview of polymyositis and dermatomyositis","volume":"51","author":"Findlay","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2022.103114_bb0490","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0495","doi-asserted-by":"crossref","first-page":"309","DOI":"10.55563\/clinexprheumatol\/8xj0b9","article-title":"Defining anti-synthetase syndrome: a systematic literature review","volume":"40","author":"Zanframundo","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0500","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103114_bb0505","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10067-015-3139-z","article-title":"Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis","volume":"35","author":"Xu","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0510","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103114_bb0515","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1684\/ejd.2019.3634","article-title":"Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease","volume":"29","author":"Motegi","year":"2019","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0520","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rmed.2013.01.014","article-title":"The prognostic value of HRCT in myositis-associated interstitial lung disease","volume":"107","author":"Tanizawa","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0525","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103114_bb0530","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.chest.2020.04.057","article-title":"Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model","volume":"158","author":"Lian","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2022.103114_bb0535","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy","volume":"40","author":"Ge","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"84","key":"10.1016\/j.autrev.2022.103114_bb0540","first-page":"1245","article-title":"Diagnosis and management of rheumatoid arthritis","volume":"1","author":"Wasserman","year":"2011","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.autrev.2022.103114_bb0545","first-page":"423","article-title":"Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis","volume":"34","author":"Yildirim","year":"2004","journal-title":"Ann Clin Lab Sci."},{"key":"10.1016\/j.autrev.2022.103114_bb0550","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/BF02886742","article-title":"Relationship between serum ferritin, iron stores and disease activity in rheumatoid arthritis","volume":"16","author":"Palermo","year":"1986","journal-title":"Ric Clin Lab."},{"key":"10.1016\/j.autrev.2022.103114_bb0555","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1620\/tjem.168.499","article-title":"Synovial fluid ferritin in traumatic hemarthrosis, rheumatoid arthritis and osteoarthritis","volume":"168","author":"Abe","year":"1992","journal-title":"Tohoku J Exp Med."},{"key":"10.1016\/j.autrev.2022.103114_bb0560","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5152\/eurjrheumatol.2014.032","article-title":"The correlation between ferritin level and acute phase parameters in rheumatoid arthritis and systemic lupus erythematosus","volume":"1","author":"Seyhan","year":"2014","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0565","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jns.2016.12.039","article-title":"Disease progression and oxidative stress are associated with higher serum ferritin levels in patients with multiple sclerosis","volume":"373","author":"Ferreira","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2022.103114_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102778","article-title":"Ferritin - from iron, through inflammation and autoimmunity, to COVID-19","volume":"126","author":"Mahroum","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103114_bb0575","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0006-8993(98)01360-2","article-title":"Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients","volume":"821","author":"LeVine","year":"1999","journal-title":"Brain Res"},{"key":"10.1016\/j.autrev.2022.103114_bb0580","first-page":"91","article-title":"Ferritin and prolactin levels in multiple sclerosis","volume":"13","author":"Da Costa","year":"2011","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2022.103114_bb0585","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/01.CCM.0000298158.12101.41","article-title":"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008","volume":"36","author":"Dellinger","year":"2008","journal-title":"Crit Care Med"},{"issue":"8","key":"10.1016\/j.autrev.2022.103114_bb0590","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2022.103114_bb0600","doi-asserted-by":"crossref","first-page":"435","DOI":"10.18821\/0869-2084-2019-64-7-435-442","article-title":"Inflammation markers and bloodstream infection (review of literature)","volume":"64","author":"Kargaltseva","year":"2019","journal-title":"Klin Lab Diagn"},{"key":"10.1016\/j.autrev.2022.103114_bb0605","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.burns.2008.01.014","article-title":"Comparison of WBC, ESR, CRP and PCT serum levels in septic and non-septic burn cases","volume":"34","author":"Barati","year":"2008","journal-title":"Burns"},{"key":"10.1016\/j.autrev.2022.103114_bb0610","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1177\/0009922819837352","article-title":"C-Reactive protein and ferritin are associated with organ dysfunction and mortality in hospitalized children","volume":"58","author":"Horvat","year":"2019","journal-title":"Clin Pediatr"},{"key":"10.1016\/j.autrev.2022.103114_bb0615","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF01058569","article-title":"Body iron status in critically ill patients: significance of serum ferritin","volume":"15","author":"Bobbio-Pallavicini","year":"1989","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0620","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/CCM.0000000000004131","article-title":"Hyperferritinemia in Critically Ill Patients","volume":"48","author":"Lachmann","year":"2020","journal-title":"Crit Care Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0625","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/j.1651-2227.2007.00564.x","article-title":"Ferritin levels in children with severe sepsis and septic shock","volume":"96","author":"Garcia","year":"2007","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.autrev.2022.103114_bb0630","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1097\/PCC.0b013e31820abca8","article-title":"Very high serum ferritin levels are associated with increased mortality and critical care in pediatric patients","volume":"12","author":"Bennett","year":"2011","journal-title":"Pediatr Crit Care Med"},{"issue":"8","key":"10.1016\/j.autrev.2022.103114_bb0635","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA."},{"issue":"1","key":"10.1016\/j.autrev.2022.103114_bb0640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rmv.2146","article-title":"Predictors of COVID-19 severity: A literature review","volume":"31","author":"Gallo Marin","year":"2021","journal-title":"Rev Med Virol."},{"issue":"10223","key":"10.1016\/j.autrev.2022.103114_bb0645","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"7798","key":"10.1016\/j.autrev.2022.103114_bb0650","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.autrev.2022.103114_bb0655","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.12688\/f1000research.26186.1","article-title":"Predictors of COVID-19 severity: a systematic review and meta-analysis","volume":"9","author":"Mudatsir","year":"2020","journal-title":"F1000Res."},{"issue":"8","key":"10.1016\/j.autrev.2022.103114_bb0660","first-page":"516","article-title":"Ferritin and severe COVID-19, from clinical observations to pathogenic implications and therapeutic perspectives","volume":"22","author":"Ruscitti","year":"2020","journal-title":"Isr Med Assoc J."},{"key":"10.1016\/j.autrev.2022.103114_bb0665","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3390\/pathogens10060692","article-title":"Description and analysis of cytokine storm in registered COVID-19 clinical trials: a systematic review","volume":"10","author":"Eljaaly","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.autrev.2022.103114_bb0670","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23618","article-title":"Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis","volume":"34","author":"Cheng","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.autrev.2022.103114_bb0675","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2022.103114_bb0680","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"issue":"10","key":"10.1016\/j.autrev.2022.103114_bb0685","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137799","article-title":"The laboratory tests and host immunity of COVID-19 patients with different severity of illness","volume":"5","author":"Wang","year":"2020","journal-title":"JCI Insight."},{"key":"10.1016\/j.autrev.2022.103114_bb0690","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3390\/jcm9051548","article-title":"Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for Covid-19 infection in lombardy","volume":"9","author":"Cecconi","year":"2020","journal-title":"Italy. J Clin Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0695","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijid.2022.02.007","article-title":"Hospitalized patients with breakthrough COVID-19: Clinical features and poor outcome predictors","volume":"118","author":"Moreno-Perez","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.autrev.2022.103114_bb0700","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3319","article-title":"Diabetes is a risk factor for the progression and prognosis of COVID-19","author":"Guo","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0705","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.27172","article-title":"Association of serum ferritin levels and methylprednisolone treatment with outcomes in nonintubated patients with severe COVID-19 PNEUMONIA","volume":"4","author":"Papamanoli","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.autrev.2022.103114_bb0710","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0715","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jama.2021.9508","article-title":"Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial","volume":"326","author":"Caricchio","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2022.103114_bb0720","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0725","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jiph.2021.10.024","article-title":"Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients","volume":"15","author":"Sarhan","year":"2022","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.autrev.2022.103114_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106334","article-title":"Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial","volume":"57","author":"Faqihi","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.autrev.2022.103114_bb0735","article-title":"The Spectrum of Manifestations of Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV2) infection in children: what we can learn from Multisystem Inflammatory Syndrome in Children (MIS-C)","volume":"8","author":"Panaro","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2022.103114_bb0740","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.15585\/mmwr.mm6940e1","article-title":"Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020","volume":"69","author":"Morris","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.autrev.2022.103114_bb0745","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(20)31103-X","article-title":"An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study","volume":"395","author":"Verdoni","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2022.103114_bb0750","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.15585\/mmwr.mm6932e2","article-title":"California MIS-C Response Team. COVID-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020","volume":"69","author":"Godfred-Cato","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.autrev.2022.103114_bb0755","author":"Royal College of Pediatrics and Child Health"},{"key":"10.1016\/j.autrev.2022.103114_bb0765","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/1744666X.2021.1847643","article-title":"The wide spectrum of Kawasaki-like disease associated with SARS-CoV-2 infection","volume":"16","author":"Berardicurti","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2022.103114_bb0770","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S2352-4642(21)00050-X","article-title":"Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study","volume":"5","author":"Abrams","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.autrev.2022.103114_bb0775","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1002\/jmv.26951","article-title":"The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19: A meta-analysis","volume":"93","author":"Zhao","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.autrev.2022.103114_bb0780","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0785","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1111\/crj.12918","article-title":"Prognostic evaluation of serum ferritin in acute exacerbation of idiopathic pulmonary fibrosis","volume":"12","author":"Enomoto","year":"2018","journal-title":"Clin Respir J"},{"key":"10.1016\/j.autrev.2022.103114_bb0790","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1365-2141.2009.07774.x","article-title":"Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation","volume":"146","author":"Mahindra","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2022.103114_bb0795","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s12032-010-9496-1","article-title":"Hyperferritinemia is associated with low incidence of graft versus host disease, high relapse rate, and impaired survival in patients with blood disorders receiving allogeneic hematopoietic stem cell grafts","volume":"28","author":"Wahlin","year":"2011","journal-title":"Med Oncol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103114_bb0800","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ajh.23188","article-title":"Does iron overload really matter in stem cell transplantation?","volume":"87","author":"Armand","year":"2012","journal-title":"Am J Hematol."},{"key":"10.1016\/j.autrev.2022.103114_bb0805","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.bbmt.2010.09.006","article-title":"Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation","volume":"17","author":"Armand","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.autrev.2022.103114_bb0810","first-page":"245","article-title":"The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis","volume":"1836","author":"Alkhateeb","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/j.autrev.2022.103114_bb0815","first-page":"605","article-title":"Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapy. PLoS One 2012;7:e51379. doi: 10.1371\/journal.pone.0051379. Stevens RG, Beasley RP, Blumberg BS. Iron-binding proteins and risk of cancer in Taiwan","volume":"76","author":"Alkhateeb","year":"1986","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"10.1016\/j.autrev.2022.103114_bb0820","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/ijc.2910430304","article-title":"Increased serum ferritin in chronic liver disease: a risk factor for primary hepatocellular carcinoma","volume":"43","author":"Hann","year":"1989","journal-title":"Int J Cancer."},{"key":"10.1016\/j.autrev.2022.103114_bb0825","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/jn\/115.3.369","article-title":"Influence of iron on in vivo proliferation and lethality of L1210 cells","volume":"115","author":"Bergeron","year":"1985","journal-title":"J Nutr"},{"key":"10.1016\/j.autrev.2022.103114_bb0830","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2022.103114_bb0835","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/ijms17040548","article-title":"Role of serum uric acid and ferritin in the development and progression of NAFLD","volume":"17","author":"Lombardi","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2022.103114_bb0840","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.24706","article-title":"NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease","volume":"55","author":"Kowdley","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2022.103114_bb0845","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11894-011-0234-4","article-title":"Iron metabolism in nonalcoholic fatty liver disease","volume":"14","author":"Nelson","year":"2012","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.autrev.2022.103114_bb0850","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s10620-009-0771-y","article-title":"Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation","volume":"55","author":"Yoneda","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2022.103114_bb0855","doi-asserted-by":"crossref","first-page":"90","DOI":"10.15171\/mejdd.2018.96","article-title":"Correlation Between Serum Ferritin Level And Histopathological Disease Severity In Non-Alcoholic Fatty Liver Disease","volume":"10","author":"Modares Mousavi","year":"2018","journal-title":"Middle East J Dig Dis"},{"issue":"1","key":"10.1016\/j.autrev.2022.103114_bb0860","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/ijmr.IJMR_1768_17","article-title":"Obesity subtypes, related biomarkers & heterogeneity","volume":"151","author":"Mayoral","year":"2020","journal-title":"Indian J Med Res."},{"key":"10.1016\/j.autrev.2022.103114_bb0865","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.ijo.0801561","article-title":"Association of serum ferritin and indices of body fat distribution and obesity in Mexican American men--the Third National Health and Nutrition Examination Survey","volume":"25","author":"Gillum","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.autrev.2022.103114_bb0870","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.2337\/dc12-0543","article-title":"Association of serum ferritin and the development of metabolic syndrome in middle-aged Korean men: a 5-year follow-up study","volume":"35","author":"Park","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2022.103114_bb0875","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior Phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0880","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1258\/ebm.2009.009229","article-title":"The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice","volume":"235","author":"Zhang","year":"2010","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.autrev.2022.103114_bb0885","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/cc11256","article-title":"Turkish Secondary HLH\/MAS Critical Care Study Group. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction syndrome\/macrophage activation syndrome: what is the treatment?","volume":"16","author":"Demirkol","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.autrev.2022.103114_bb0890","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1097\/PCC.0000000000000896","article-title":"High-volume hemofiltration in critically ill patients with secondary hemophagocytic lymphohistiocytosis\/macrophage activation syndrome: a prospective study in the PICU","volume":"17","author":"Cui","year":"2016","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0895","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2020-217618","article-title":"Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?","volume":"79","author":"Ruscitti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103114_bb0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102562","article-title":"Cytokine storm syndrome in severe COVID-19","volume":"19","author":"Ruscitti","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0905","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103114_bb0910","doi-asserted-by":"crossref","first-page":"2001618","DOI":"10.1183\/13993003.01618-2020","article-title":"Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?","volume":"56","author":"Giannini","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2022.103114_bb0915","doi-asserted-by":"crossref","first-page":"274","DOI":"10.55563\/clinexprheumatol\/di1083","article-title":"Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies","volume":"40","author":"Cavagna","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0925","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/annrheumdis-2020-218048","article-title":"Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences","volume":"79","author":"Ruscitti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103114_bb0930","first-page":"1247","article-title":"Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis","volume":"38","author":"Berardicurti","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2022.103114_bb0935","article-title":"Should we stimulate or suppress immune responses in COVID-19?","volume":"19","author":"Jamilloux","year":"2020","journal-title":"Cytokine and anti-cytokine interventions. Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0940","doi-asserted-by":"crossref","first-page":"102569","DOI":"10.1016\/j.autrev.2020.102569","article-title":"Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review","volume":"19","author":"Alijotas-Reig","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102570","article-title":"Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view","volume":"19","author":"Kronbichler","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102738","article-title":"The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts\u2019 Consensus","volume":"20","author":"Giacomelli","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0955","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2018.08.003","article-title":"Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis","volume":"18","author":"Giacomelli","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103114_bb0960","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.autrev.2017.07.012","volume":"16","author":"Giacomelli","year":"2017","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222000842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222000842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:26:33Z","timestamp":1761600393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997222000842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":187,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1568997222000842"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103114","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103114"}}